On June 4, 2021 Lvgen Biopharma, a biotech company focused on developing innovative immuno-oncology therapeutics, reported that it will present a Trials in Progress poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (ASCO) (Free ASCO Whitepaper), to be held in a virtual format from June 4 to 8, 2021 (Press release, Lyvgen Biopharma, JUN 4, 2021, View Source [SID1234583587]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Trials in Progress poster presentation summarizes the safety profile, antitumor activity observed in a phase I clinical trial (NCT04130542) in collaboration with Merck & Co., Inc., Kenilworth, New Jersey, U.S.A., known as MSD outside of the U.S. and Canada. The trial is evaluating LVGN6051, a second generation 4-1BB (CD137) agonist antibody based on Lyvgen proprietary xLinkAb platform, as monotherapy or in combination with KEYTRUDA (pembrolizumab), MSD’s anti-PD-1 therapy, in adult patients with advanced malignancies. No MTD was reached at 7 mg/kg monotherapy and 4 mg/kg q3w monotherapy was determined as RP2D. Preliminary antitumor activity in late stage cancer patients was observed. Combination with pembrolizumab induced rapid antitumor responses in advanced cancer patients with immune-cold tumor or relapsed from prior immunotherapies.
Presentation Details:
Abstract title: Early safety and efficacy from a phase I open-label clinical trial of CD137 (4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab.
Abstract number: 2521
Poster Session: Developmental Therapeutics—Immunotherapy
The 2021 ASCO (Free ASCO Whitepaper) Annual Meeting will take place virtually on June 4 – 8, 2021 via the ASCO (Free ASCO Whitepaper) website, View Source
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
About LVGN6051
LVGN6051 is xLinkAb anti-4-1BB (CD137) agonist mAb that has been designed to activate 4-1BB optimally in tumor microenvironment by targeting both 4-1BB and FcγRIIB. LVGN6051 strikes a balance between antitumor efficacy and safety by agonizing 4-1BB only in the presence of FcγRIIB, which is expressed on immune cells enriched in the tumor microenvironment, including B cells, dendritic cells and granulocytes.